ClinicalTrials.gg
Enrolling by invitationNCT07942090FAPI-MN-2020Updated Nov 17, 2026

Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological Pathology

An interventional study of 68Ga-FAPI in Lung Cancer Diagnosis, Head and Neck Cancer (H&N) and Breast Cancer, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Jun 2021, registered Mar 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 134 studies in Head and Neck Neoplasms with a site in Italy — 43 open to participants now, 57 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.

Planned enrollment
41st of 97
200 · median 160
Started
2021
with 10 others
No phase
20 of 134
10 open now
Primary completion
2030-06
later than 48 of 56 live
Registered
129th of 134
by date

Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 41st largest by planned enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2021, is one of 20 with no phase, reaches primary completion later than 48 of the 56 other live ones, and was the 129th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

43 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Head and Neck Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

Read the detailed description

Studied population Approximately 200 patients will be enrolled with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

Patients enrolled must satisfy all the inclusion criteria and must sign an informed consent. The informed consent will be signed by the patient in the nuclear medicine department before the performance of any experimental procedure.

Primary aim

Secondary aim

To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

To evaluate accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

Primary endpoint accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

Secondary enpoint accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.

03

Conditions studied

  • Lung Cancer Diagnosis
  • Head and Neck Cancer (H&N)
  • Breast Cancer
  • Ovarian Cancer

Keywords

  • FAPI PET/CT
  • lung cancer
  • H&N cancer
  • oncological patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria • Age ≥18 years old

    • Both sexes
    • Patients with oncological disease suspicion/ new diagnosis or with a previously treated tumour (with previous treatments performed at least 3 months before enrollment) and with an inconclusive or equivocal [18F]F-FDG PET/CT, especially cases of:
  • Suspect primary or secondary (lymph-nodes or distant ) lesions with absent/faint FDG uptake or low TBR;
  • And/or suspect primary or secondary (lymph-nodes or distant metastases) lesions in a site of phisiological FDG uptake (such as brain or liver) or in sites in which FDG has a low sensitivity (i.e. peritoneal carcinomatosis, esophageal-gastro-intestinal tract);
  • And/or low glucose metabolism tumour hystotypes (i.e. renal clear cell carcinoma, mucinous mammary tumours, well differentiated HCC);
  • And/or differential diagnosis between tumour and inflammation (i.e. determining lymph-nodes benign or malignant nature in head/neck cancers, differential diagnosis between inflammation or malignant tissue in sarcomas).

    • Signed

Exclusion Criteria: Exclusion Criteria • Pregnancy. In order to rule out pregnancy a β-hCG blood test will be performed in women of childbearing age.

  • Breastfeeding
  • Patients in emergency situations or unfit to plead.
  • History of allergic reactions or to the active substance, to any of the , or to any of the components of the radiolabeled radiopharmaceutical
  • to PET / CT examination for patients unable to perform PET due to weight, claustrophobia or the inability to remain still for the duration of the examination
  • Participation in a clinical trial in which an drug was administered within 30 days or 5 half-lives before the study drug
  • Patients with impaired renal function;
  • Patients with impaired liver function;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Interventions

  • Other68Ga-FAPI

    Oncological patients receive the injection of 68Ga-FAPI

06

What researchers measure

Primary outcomes

  1. diagnostic performance

    sensitivity, specificity, AUC, detection rate, accuracy, positive and negative predictive value compared to the reference standard.

    Time frame: 9 years

07

Study locations

1 site
08

References and documents

Publications

  • Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28. PubMed 32222810 ↗
  • Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jager D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2. PubMed 30072500 ↗
  • Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Rohrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jager D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6. PubMed 30954939 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2030, 108 months after the start.

Of 437 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 108 months is above that.

Counting every sponsor, half of 455 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Nov 17, 2026
StartActual
Jun 3, 2021
Primary completionEst.
Jun 3, 2030
CompletionEst.
Jun 3, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942090
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jun 3, 2021
Primary completion
Jun 3, 2030 (estimated)
Completion
Jun 3, 2030 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion